PHIO
insider transactionsPhio Pharmaceuticals Corp. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 365d
+20.0K
20.0K buy · 0 sell
Net value · 365d
$22.3K
$22.3K in · $0 out
Sentiment · 365d
Net buying
100% buying · 0% selling
Open-market trades · 365d
4
20.0K buy · 0 sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Grant·A
Director
$0
16.6K sh
Own +89%
-
Grant·A
Director
$0
16.6K sh
Own +103%
-
Grant·A
Chief Financial Officer
$0
47.0K sh
Own +100%
-
Grant·A
Director
$0
23.8K sh
Own +170%
-
Grant·A
Chairman, Pres. & CEO
$0
120.0K sh
Own +41%
-
Grant·A
Director
$0
18.5K sh
Own +68%
-
Buy·P
Chairman, Pres. & CEO
$5.2K
5.0K sh · $1.03
Own +2%
-
Buy·P
Chairman, Pres. & CEO
$5.1K
5.0K sh · $1.02
Own +2%
-
Buy·P
Chairman, Pres. & CEO
$5.7K
5.0K sh · $1.14
Own +2%
-
Buy·P
Chairman, Pres. & CEO
$6.3K
5.0K sh · $1.27
Own +2%
-
Grant·A
Director
$0
18.8K sh
Own +225%
-
Grant·A
Chairman, Pres. & CEO
$0
250.0K sh
Own +1167%
-
Other·F
Chairman, Pres. & CEO
$9.5K
4.1K sh · $2.32
Own -16%
-
Grant·A
Director
$0
14.0K sh
Own New
-
Grant·A
VP, Finance and Administration
$0
47.0K sh
Own New
-
Grant·A
Director
$0
16.2K sh
Own +688%
-
Grant·A
Director
$0
14.7K sh
Own +1085%
-
Grant·A
Director
$0
23.0K sh
Own +147%
-
Grant·A
Director
$0
23.1K sh
Own +147%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Feb 5, 2026 | Lockshin Curtis | Grant A | 16.6K | $0 |
| Feb 5, 2026 | Freeman Jonathan E | Grant A | 16.6K | $0 |
| Feb 5, 2026 | Carson Lisa Cabott KEY | Grant A | 47.0K | $0 |
| Feb 5, 2026 | Deming David H | Grant A | 23.8K | $0 |
| Feb 5, 2026 | Bitterman Robert J KEY | Grant A | 120.0K | $0 |
| Feb 5, 2026 | BRADFORD PATRICIA A | Grant A | 18.5K | $0 |
| Dec 31, 2025 | Bitterman Robert J KEY | Buy P | 5.0K | $5.2K |
| Dec 23, 2025 | Bitterman Robert J KEY | Buy P | 5.0K | $5.1K |
| Nov 21, 2025 | Bitterman Robert J KEY | Buy P | 5.0K | $5.7K |
| Nov 18, 2025 | Bitterman Robert J KEY | Buy P | 5.0K | $6.3K |
| Sep 11, 2025 | BRADFORD PATRICIA A | Grant A | 18.8K | $0 |
| Sep 11, 2025 | Bitterman Robert J KEY | Grant A | 250.0K | $0 |
| Sep 11, 2025 | Bitterman Robert J KEY | Other F | 4.1K | $9.5K |
| Sep 11, 2025 | Deming David H | Grant A | 14.0K | $0 |
| Sep 11, 2025 | Carson Lisa Cabott | Grant A | 47.0K | $0 |
| Sep 11, 2025 | Lockshin Curtis | Grant A | 16.2K | $0 |
| Sep 11, 2025 | Freeman Jonathan E | Grant A | 14.7K | $0 |
| Sep 11, 2025 | Ferrara Robert L | Grant A | 23.0K | $0 |
| Sep 11, 2025 | Ferrara Robert L | Grant A | 23.1K | $0 |
About PHIO insider trading
This page tracks insider transactions for Phio Pharmaceuticals Corp. (PHIO) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.